The FDA Has Accepted For Review GSK's Nucala (Mepolizumab) As An Add-on Maintenance Treatment For Patients With Chronic Obstructive Pulmonary Disease With An Eosinophilic Phenotype, With Prescription Drug User Fee Act Date Is 7 May 2025

-0.14%

GlaxoSmithKline plc Sponsored ADR

GSK

48.81

-0.14%

Submission supported by MATINEE data showing a significant and clinically meaningful reduction in annualized rate of moderate/severe exacerbations compared with placebo.
Nucala could be the first approved biologic with monthly dosing for patients with COPD.
COPD affects more than 14 million people in the US with estimates of 500,000 hospitalizations and up to 1.3 million emergency department visits each year.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.